TGTX
TG Therapeutics, Inc.
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Revenue | 616.3M | 329.0M | 233.7M | 2.8M | 6.7M | 152,000 | 152,000 | 152,000 | 152,000 | 152,000 |
| Cost of Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||||
| R&D Expenses | — | — | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — | — | — | — | — |
| Operating Income | 123.3M | 41.9M | 20.6M | -218.3M | -344.8M | -273.6M | -169.1M | -174.4M | -118.7M | -79.0M |
| EBITDA | — | — | — | — | — | — | — | — | — | — |
| Below the Line | ||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — | — | — | — | — |
| Net Income | 447.2M | 23.4M | 12.7M | -223.8M | -348.1M | — | — | — | — | — |
| Per Share | ||||||||||
| EPS (basic) | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — |
| Shares | ||||||||||
| Basic Shares | — | — | — | — | — | — | — | — | — | — |
| Diluted Shares | 161M | 160M | 149M | 135M | 132M | 115M | 109M | 84M | 73M | 57M |